Maravai LifeSciences Holdings Inc
NASDAQ:MRVI

Watchlist Manager
Maravai LifeSciences Holdings Inc Logo
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Watchlist
Price: 5.33 USD 3.9%
Market Cap: 1.3B USD
Have any thoughts about
Maravai LifeSciences Holdings Inc?
Write Note

Operating Margin
Maravai LifeSciences Holdings Inc

-16.3%
Current
35%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-16.3%
=
Operating Profit
-45.2m
/
Revenue
276.9m

Operating Margin Across Competitors

Country US
Market Cap 1.3B USD
Operating Margin
-16%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 202B USD
Operating Margin
17%
Country US
Market Cap 166.7B USD
Operating Margin
21%
Country KR
Market Cap 66.8T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.7B USD
Operating Margin
24%
Country US
Market Cap 36.2B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24.1B USD
Operating Margin
20%
Country CN
Market Cap 164.4B CNY
Operating Margin
27%
No Stocks Found

Maravai LifeSciences Holdings Inc
Glance View

Market Cap
1.3B USD
Industry
Life Sciences Tools & Services

Maravai LifeSciences Holdings Inc. operates in the niche yet burgeoning market of life sciences, where its business revolves around the creation and supply of essential products and services for biotechnology workflows. Founded in 2014 and headquartered in San Diego, California, Maravai specializes in providing key components for the development of diagnostics and therapeutics. A significant portion of its revenue is driven by its business unit, TriLink BioTechnologies, which is instrumental in the synthesis of nucleic acids, notably mRNA and modified nucleotides – critical for the development of mRNA vaccines like those used in combating COVID-19. This has positioned Maravai as a crucial player during the pandemic, spotlighting its capability to provide high-quality inputs that support leading-edge scientific innovations. The company’s financial engine is powered by its diversified product offerings across three main segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. Beyond just supplying raw materials, Maravai elevates its contributions by ensuring these components meet rigorous quality standards necessary for clinical applications. The robust demand for both biopharmaceutical innovation and bioprotection has allowed Maravai to capitalize on trends such as personalized medicine and gene therapy. By navigating these influential currents in the biotechnology space, Maravai LifeSciences not only gains from direct sales of its products but also cultivates long-standing partnerships across pharmaceutical and research organizations, underscoring its integral role in the ongoing evolution of life sciences.

MRVI Intrinsic Value
2.89 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-16.3%
=
Operating Profit
-45.2m
/
Revenue
276.9m
What is the Operating Margin of Maravai LifeSciences Holdings Inc?

Based on Maravai LifeSciences Holdings Inc's most recent financial statements, the company has Operating Margin of -16.3%.